[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577593":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":47,"centralContacts":51,"locations":57,"responsibleParty":236,"collaborators":40,"id":238,"slug":239,"hasResults":240,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":40,"eligibilityCriteria":244,"healthyVolunteers":240,"sex":245,"minAge":246,"maxAge":40,"enrollmentInfo":247,"targetDuration":40,"studyType":250,"phases":251,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":60,"whyStopped":40,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8,14,19,22,25,28,31],{"label":9,"type":10,"description":11,"interventionNames":12},"JNJ-101556143 Phase 1 Part 1 - Dose Escalation","EXPERIMENTAL","Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)",[13],"Drug: JNJ-101556143 Formulation 1",{"label":15,"type":10,"description":11,"interventionNames":16},"JNJ-101556143 Phase 1 Part 2 - Formulation Exploration",[13,17,18],"Drug: JNJ-101556143 Formulation 2","Drug: JNJ-101556143 Formulation 3",{"label":20,"type":10,"description":11,"interventionNames":21},"JNJ-101556143 Phase 2 Part 1 - Dose Optimization",[13],{"label":23,"type":10,"description":11,"interventionNames":24},"Phase 2 Part 2A - SOAR",[13],{"label":26,"type":10,"description":11,"interventionNames":27},"Phase 2 Part 2B - HSPC Expansion",[13],{"label":29,"type":10,"description":11,"interventionNames":30},"Phase 2 Part 2C - HSPC Expansion",[13],{"label":32,"type":10,"description":11,"interventionNames":33},"Phase 2 Part 2D - HSPC Expansion",[13],[35,41,44],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","JNJ-101556143 Formulation 1","Experimental: Oral JNJ-101556143",[9,15,20,23,26,29,32],null,{"type":36,"name":42,"description":38,"armGroupLabels":43,"otherNames":40},"JNJ-101556143 Formulation 2",[15],{"type":36,"name":45,"description":38,"armGroupLabels":46,"otherNames":40},"JNJ-101556143 Formulation 3",[15],[48],{"name":49,"affiliation":5,"role":50},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[52],{"name":53,"role":54,"phone":55,"phoneExt":40,"email":56},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[58,72,81,91,101,111,121,131,141,151,160,170,180,190,196,206,215,225],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":40},"Rocky Mountain Cancer Center","RECRUITING","Colorado Springs","Colorado","80909","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-104.82136,38.83388,{"lat":70,"lon":69},{"facility":73,"status":60,"city":74,"state":62,"zip":75,"country":64,"countryCode":65,"cosmosGeoPoint":76,"geoPoint":80,"contacts":40},"Sarah Cannon Research Institute 1","Denver","80218",{"type":67,"coordinates":77},[78,79],-104.9847,39.73915,{"lat":79,"lon":78},{"facility":82,"status":60,"city":83,"state":84,"zip":85,"country":64,"countryCode":65,"cosmosGeoPoint":86,"geoPoint":90,"contacts":40},"Yale University","New Haven","Connecticut","06511",{"type":67,"coordinates":87},[88,89],-72.92816,41.30815,{"lat":89,"lon":88},{"facility":92,"status":60,"city":93,"state":94,"zip":95,"country":64,"countryCode":65,"cosmosGeoPoint":96,"geoPoint":100,"contacts":40},"Florida Cancer Specialists","Sarasota","Florida","34232",{"type":67,"coordinates":97},[98,99],-82.53065,27.33643,{"lat":99,"lon":98},{"facility":102,"status":60,"city":103,"state":104,"zip":105,"country":64,"countryCode":65,"cosmosGeoPoint":106,"geoPoint":110,"contacts":40},"XCancer Research Network LCMC Health EJGH","Metairie","Louisiana","70006",{"type":67,"coordinates":107},[108,109],-90.15285,29.98409,{"lat":109,"lon":108},{"facility":112,"status":60,"city":113,"state":114,"zip":115,"country":64,"countryCode":65,"cosmosGeoPoint":116,"geoPoint":120,"contacts":40},"Dana Farber Mass General Brigham Cancer Care Inc","Boston","Massachusetts","02114",{"type":67,"coordinates":117},[118,119],-71.05977,42.35843,{"lat":119,"lon":118},{"facility":122,"status":60,"city":123,"state":124,"zip":125,"country":64,"countryCode":65,"cosmosGeoPoint":126,"geoPoint":130,"contacts":40},"South Texas Accelerated Research Therapeutics, LLC (START)","Grand Rapids","Michigan","49546",{"type":67,"coordinates":127},[128,129],-85.66809,42.96336,{"lat":129,"lon":128},{"facility":132,"status":60,"city":133,"state":134,"zip":135,"country":64,"countryCode":65,"cosmosGeoPoint":136,"geoPoint":140,"contacts":40},"Urology Cancer Center, PC","Omaha","Nebraska","68130",{"type":67,"coordinates":137},[138,139],-95.94043,41.25626,{"lat":139,"lon":138},{"facility":142,"status":60,"city":143,"state":144,"zip":145,"country":64,"countryCode":65,"cosmosGeoPoint":146,"geoPoint":150,"contacts":40},"Memorial Sloan Kettering Cancer Center","Long Island City","New York","11101",{"type":67,"coordinates":147},[148,149],-73.94875,40.74482,{"lat":149,"lon":148},{"facility":152,"status":60,"city":153,"state":144,"zip":154,"country":64,"countryCode":65,"cosmosGeoPoint":155,"geoPoint":159,"contacts":40},"Associated Medical Professionals","Syracuse","13210",{"type":67,"coordinates":156},[157,158],-76.14742,43.04812,{"lat":158,"lon":157},{"facility":161,"status":60,"city":162,"state":163,"zip":164,"country":64,"countryCode":65,"cosmosGeoPoint":165,"geoPoint":169,"contacts":40},"Duke University Medical Center","Durham","North Carolina","27710",{"type":67,"coordinates":166},[167,168],-78.89862,35.99403,{"lat":168,"lon":167},{"facility":171,"status":60,"city":172,"state":173,"zip":174,"country":64,"countryCode":65,"cosmosGeoPoint":175,"geoPoint":179,"contacts":40},"Carolina Urologic Research Center","Myrtle Beach","South Carolina","29572",{"type":67,"coordinates":176},[177,178],-78.88669,33.68906,{"lat":178,"lon":177},{"facility":181,"status":60,"city":182,"state":183,"zip":184,"country":64,"countryCode":65,"cosmosGeoPoint":185,"geoPoint":189,"contacts":40},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":67,"coordinates":186},[187,188],-86.78444,36.16589,{"lat":188,"lon":187},{"facility":191,"status":60,"city":182,"state":183,"zip":192,"country":64,"countryCode":65,"cosmosGeoPoint":193,"geoPoint":195,"contacts":40},"Urology Associates","37209",{"type":67,"coordinates":194},[187,188],{"lat":188,"lon":187},{"facility":197,"status":60,"city":198,"state":199,"zip":200,"country":64,"countryCode":65,"cosmosGeoPoint":201,"geoPoint":205,"contacts":40},"NEXT Oncology","Austin","Texas","78758",{"type":67,"coordinates":202},[203,204],-97.74306,30.26715,{"lat":204,"lon":203},{"facility":207,"status":60,"city":208,"state":199,"zip":209,"country":64,"countryCode":65,"cosmosGeoPoint":210,"geoPoint":214,"contacts":40},"MD Anderson Cancer Center","Houston","77030",{"type":67,"coordinates":211},[212,213],-95.36327,29.76328,{"lat":213,"lon":212},{"facility":216,"status":60,"city":217,"state":218,"zip":219,"country":64,"countryCode":65,"cosmosGeoPoint":220,"geoPoint":224,"contacts":40},"Virginia Clinical Research","Norfolk","Virginia","23502",{"type":67,"coordinates":221},[222,223],-76.28522,36.84681,{"lat":223,"lon":222},{"facility":226,"status":60,"city":227,"state":40,"zip":228,"country":229,"countryCode":230,"cosmosGeoPoint":231,"geoPoint":235,"contacts":40},"The Royal Marsden NHS Trust","Sutton","SM2 5PT","United Kingdom","UK",{"type":67,"coordinates":232},[233,234],-0.2,51.35,{"lat":234,"lon":233},{"type":237,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100577593","phase-1-study-of-hld-0915-in-patients-with-metastatic-prostate-cancer-100577593",false,"NCT06800313","Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","Phase 1\u002F2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","Patients must meet the following criteria to be eligible study participation:\n\nKey Inclusion Criteria:\n\nAll Study Arms (Phase 1 Part 1 \\& 2, Phase 2 Part 1, Part 2A, 2B, 2C \\& 2D):\n\nMales ≥ 18 years old Histological, pathological, and\u002For cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication\n\nmCRPC Arms: (Phase 1 Part 1 \\& 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen\n\nSOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng\u002FmL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI\n\nmHSPC arms (Phase 2 Part 2B, 2C \\& 2D) serum testosterone \\>150ng\u002Fml mHSPC with distant metastatic disease based on conventional imaging and PSA \\>2.0 ng\u002FmL\n\nKey Exclusion Criteria:\n\nAll arms (Phase 1 Part 1 \\& 2, Phase 2 Part 1, Part 2A, 2B, 2C \\& 2D):\n\nHas experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of \\>10 mg\u002Fday Prior or ongoing significant medical condition\n\nmCRPC arms: (Phase 1 Part 1 \\& 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods\n\nSOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer\n\nmHSPC arms (Phase 2 Part 2B, 2C \\& 2D) regional pelvic lymph node disease only","MALE","18 Years",{"count":248,"type":249},190,"ESTIMATED","INTERVENTIONAL",[252,253],"PHASE1","PHASE2","Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.",[256],"Metastatic Prostate Cancer",[258,259,260,261,262,263,264,265,266,267,268,269],"Prostate Cancer","RIPTAC","HLD-0915","Genital Neoplasms, Male","Urogenital Neoplasms, Male","Genital Diseases, Male","Urogenital Diseases, Male","Neoplasms, Glandular and Epithelial","Prostatic Neoplasms","Prostate Adenocarcinoma","Hormone Sensitive, Castrate Resistant","Metastatic Castrate Resistant Prostate Cancer","2026-08-19",{"date":272,"type":273},"2026-08-20","ACTUAL",{"date":275,"type":273},"2025-02-06",{"date":277,"type":249},"2028-07-11",{"name":5,"class":6},18]